Jayne B.  Hart net worth and biography

Jayne Hart Biography and Net Worth

Insider of Myriad Genetics
Jayne B. Hart joined Myriad Genetics in May 2011 as chief people officer. She has more than twenty years of professional experience in the human resources field. Prior to joining Myriad, Ms. Hart served as vice president of human resources at LANDesk Software, a global software company. Before that, she was vice president of human resources for 360networks, a wholesale telecommunications company, and at AT&T Wireless, a global telecommunications company, where she began her career.

What is Jayne B. Hart's net worth?

The estimated net worth of Jayne B. Hart is at least $2.31 million as of March 29th, 2021. Ms. Hart owns 108,128 shares of Myriad Genetics stock worth more than $2,305,289 as of March 29th. This net worth approximation does not reflect any other assets that Ms. Hart may own. Learn More about Jayne B. Hart's net worth.

How do I contact Jayne B. Hart?

The corporate mailing address for Ms. Hart and other Myriad Genetics executives is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. Myriad Genetics can also be reached via phone at (801) 584-3600 and via email at [email protected]. Learn More on Jayne B. Hart's contact information.

Has Jayne B. Hart been buying or selling shares of Myriad Genetics?

Jayne B. Hart has not been actively trading shares of Myriad Genetics in the last ninety days. Most recently, Jayne B. Hart sold 10,500 shares of the business's stock in a transaction on Monday, February 28th. The shares were sold at an average price of $25.00, for a transaction totalling $262,500.00. Learn More on Jayne B. Hart's trading history.

Who are Myriad Genetics' active insiders?

Myriad Genetics' insider roster includes Jayne Hart (Insider), Nicole Lambert (Insider), Jerry Lanchbury (Insider), Dennis Langer (Director), S. Phanstiel (Director), Richard Riggsbee (CFO), and Daniel Spiegelman (Director). Learn More on Myriad Genetics' active insiders.

Are insiders buying or selling shares of Myriad Genetics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 38,638 shares worth more than $669,460.38. The most recent insider tranaction occured on November, 1st when CFO Richard Bryan Riggsbee sold 30,000 shares worth more than $470,700.00. Insiders at Myriad Genetics own 2.0% of the company. Learn More about insider trades at Myriad Genetics.

Information on this page was last updated on 11/1/2023.

Jayne B. Hart Insider Trading History at Myriad Genetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2022Sell10,500$25.00$262,500.00View SEC Filing Icon  
9/17/2021Sell67,446$33.72$2,274,279.12View SEC Filing Icon  
3/29/2021Sell58,000$30.00$1,740,000.00108,128View SEC Filing Icon  
See Full Table

Jayne B. Hart Buying and Selling Activity at Myriad Genetics

This chart shows Jayne B Hart's buying and selling at Myriad Genetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Myriad Genetics Company Overview

Myriad Genetics logo
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $21.32
Low: $21.17
High: $21.67

50 Day Range

MA: $22.14
Low: $20.31
High: $23.59

2 Week Range

Now: $21.32
Low: $13.82
High: $24.21

Volume

581,239 shs

Average Volume

645,224 shs

Market Capitalization

$1.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96